Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Virtual Education

Presentations from the EHA2022 Congress

We are pleased to make available a couple of presentations that were first held during the EHA2022 Congress in Vienna. Presentations include; 'Non-BCR-ABL1 molecular biomarkers of prognosis in CML' and 'Mechanisms of disease progression in chronic myeloid leukemia'. 

EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

Shady Awad 1

Non-BCR-ABL1 molecular biomarkers of prognosis in CML
Dr. Shady Awad, Hematology Research Unit Helsinki,
University of Helsinki (Finland)

  • Clinical heterogeneity and biomarkers in CML
  • Somatic mutations in CP-CML
  • Epigenetic modifier gene mutations in CP-CML
  • CHIP and clonal evolution in CP-CML
  • Somatic mutations in BP-CML
  • Fusion genes and rearrangements in CML
  • Gene expression signatures (GES) as prognosis markers
  • scRNA-sequencing in CML
  • RUNX1 as an example of mutation-induced GES in BP-CML
  • Molecular biomarkers of DMR
  • Epigenetic modifier gene mutations as a biomarker for TFR
  • Challenges and prospets

This talk was first presented during the  Scientific Working Group Session – ELN-EHA-SWG for CML: 'Understanding the pathogenesis of CML' at EHA 2022

EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

Tiong Ong 1

Mechanisms of disease progression in chronic myeloid leukemia
Dr. S. Tiong Ong, Duke-NUS Medical School Singapore &
Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, NC, USA

Learning goals:

  • Understand that BP progression is characterized by a common, or 'core' transcriptome
  • Understand that polycomb complex (PCR-)-driven processes contribute to the 'core' transcriptome
  • Appreciate that a PCR-based model of CML progression identifies putative CP biomarkers
    and therapeutic strategies

This talk was first presented during the  Scientific Working Group Session – ELN-EHA-SWG for CML: 'Understanding the pathogenesis of CML' at EHA 2022

COLT Meeting 2019: CML therapy - state of science

-- Virtual Education Program: 2019 Edition

 

Presentations from the COLT Meeting 2019

We are pleased to make available a series of presentations from the COLT Meeting 2019, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, management of CML, practicalities and monitoring TFR and Ph+ALL.

Timothy Hughes

 David Yeung 3 Devendra Hiwase

Session 1: CML therapy - state of science
Chair: Prof. Tim Hughes

  • Frontline Therapy for CML 
    (Prof Tim Hughes)
  • When frontline therapy fails
    (Dr David Yeung)
  • CML - Beyond chronic phase
    (Dr Devendra Hiwase)

 

COLT Meeting 2019: CML Management, Practicalities

 

Naranie

 David Yeung 3 Susan Branford                    

Session 2: CML Management, Practicalities
Chair: Dr David Yeung

  • Managing TKI toxicities
    (Dr Naranie Shanmuganathan)
  • Allograft - still a role in CML?
    (Dr David Yeung)
  • Molecular monitoring
    (A/Prof Susan Branford)

 

COLT Meeting 2019: Monitoring TFR and Ph+ ALL

 

Susan Branford

 

 David Yeung 3                  

 

Session 3: Monitoring TFR and Ph+ ALL
Chair: Dr Naranie Shanmunagathan

  • Monitoring TFR - Challenges 
    (A/Prof Susan Branford)
  • Ph+ ALL
    (Dr David Yeung)